Your browser doesn't support javascript.
loading
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study.
De Stefano, Valerio; Ghirardi, Arianna; Masciulli, Arianna; Carobbio, Alessandra; Palandri, Francesca; Vianelli, Nicola; Rossi, Elena; Betti, Silvia; Di Veroli, Ambra; Iurlo, Alessandra; Cattaneo, Daniele; Finazzi, Guido; Bonifacio, Massimiliano; Scaffidi, Luigi; Patriarca, Andrea; Rumi, Elisa; Casetti, Ilaria Carola; Stephenson, Clemency; Guglielmelli, Paola; Elli, Elena Maria; Palova, Miroslava; Rapezzi, Davide; Erez, Daniel; Gomez, Montse; Wille, Kai; Perez-Encinas, Manuel; Lunghi, Francesca; Angona, Anna; Fox, Maria Laura; Beggiato, Eloise; Benevolo, Giulia; Carli, Giuseppe; Cacciola, Rossella; McMullin, Mary Frances; Tieghi, Alessia; Recasens, Valle; Isfort, Susanne; Marchetti, Monia; Griesshammer, Martin; Alvarez-Larran, Alberto; Vannucchi, Alessandro Maria; Rambaldi, Alessandro; Barbui, Tiziano.
Afiliación
  • De Stefano V; Institute of Hematology, Catholic University, Rome, Italy.
  • Ghirardi A; Fondazione Policlinico Universitario A. Gemelli Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
  • Masciulli A; FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.
  • Carobbio A; FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.
  • Palandri F; FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.
  • Vianelli N; Institute of Hematology "L. and A. Seràgnoli," S. Orsola-Malpighi Hospital, Bologna, Italy.
  • Rossi E; Institute of Hematology "L. and A. Seràgnoli," S. Orsola-Malpighi Hospital, Bologna, Italy.
  • Betti S; Institute of Hematology, Catholic University, Rome, Italy.
  • Di Veroli A; Fondazione Policlinico Universitario A. Gemelli Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
  • Iurlo A; Fondazione Policlinico Universitario A. Gemelli Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
  • Cattaneo D; Rete Laziale Myeloproliferative Neoplasm (MPN), Rome, Italy.
  • Finazzi G; Hematology Division, Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico-University of Milan, Milan, Italy.
  • Bonifacio M; Hematology Division, Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico-University of Milan, Milan, Italy.
  • Scaffidi L; Hematology Division, Papa Giovanni XXIII Hospital, Bergamo, Italy.
  • Patriarca A; Section of Hematology, Department of Medicine, University of Verona, Verona, Italy.
  • Rumi E; Section of Hematology, Department of Medicine, University of Verona, Verona, Italy.
  • Casetti IC; Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
  • Stephenson C; Azienda Ospedaliero Universitaria (AOU), "Maggiore della Carità," Novara, Italy.
  • Guglielmelli P; Department of Molecular Medicine, University of Pavia, Pavia, Italy.
  • Elli EM; Department of Hematology-Oncology, Fondazione IRCCS Policlinico San Matteo Pavia, Pavia, Italy.
  • Palova M; Department of Molecular Medicine, University of Pavia, Pavia, Italy.
  • Rapezzi D; Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London, United Kingdom.
  • Erez D; Center of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
  • Gomez M; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
  • Wille K; Hematology Division, Ospedale San Gerardo, Azienda Socio Sanitaria Territoriale (ASST), Monza, Italy.
  • Perez-Encinas M; Department of Hemato-oncology, University Hospital Olomouc, Olomouc, Czech Republic.
  • Lunghi F; Ematology Unit, Azienda Ospedaliera Santa Croce e Carle, Cuneo, Italy.
  • Angona A; Hematology Institute and Blood Bank, Meir Medical Center, Kfar Saba, Israel.
  • Fox ML; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Beggiato E; Hematology Department, Hospital Clínico Universitario, Valencia, Spain.
  • Benevolo G; University Clinic for Hematology and Oncology Minden, University of Bochum, Bochum, Germany.
  • Carli G; Hematology Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain.
  • Cacciola R; Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • McMullin MF; Hematology Department, Hospital del Mar, Barcelona, Spain.
  • Tieghi A; Hematology Department, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
  • Recasens V; Unit of Hematology, Department of Oncology, University of Torino, Torino, Italy.
  • Isfort S; Hematology Division, Città della Salute e della Scienza Hospital, Torino, Italy.
  • Marchetti M; Hematology Division, San Bortolo Hospital, Vicenza, Italy.
  • Griesshammer M; Haemostasis Unit, Department of Clinical and Experimental Medicine, "Policlinico-Vittorio Emanuele" Hospital, University of Catania, Catania, Italy.
  • Alvarez-Larran A; Queen's University, Belfast, United Kingdom.
  • Vannucchi AM; Hematology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio, Reggio Emilia, Italy.
  • Rambaldi A; Hematology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain.
  • Barbui T; Department of Oncology, Hematology, Hemostaseology, and Stem Cell Transplantation, University Hospital Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen, Aachen, Germany.
Blood ; 135(5): 381-386, 2020 01 30.
Article en En | MEDLINE | ID: mdl-31869407
ABSTRACT
Patients with Philadelphia-negative myeloproliferative neoplasm (MPN) are prone to the development of second cancers, but the factors associated with these events have been poorly explored. In an international nested case-control study, we recruited 647 patients with carcinoma, nonmelanoma skin cancer, hematological second cancer, and melanoma diagnosed concurrently or after MPN diagnosis. Up to 3 control patients without a history of cancer and matched with each case for center, sex, age at MPN diagnosis, date of diagnosis, and MPN disease duration were included (n = 1234). Cases were comparable to controls for MPN type, driver mutations and cardiovascular risk factors. The frequency of thrombosis preceding MPN was similar for cases and controls (P = .462). Thrombotic events after MPN and before second cancer were higher in cases than in controls (11.6% vs 8.1%; P = .013), because of a higher proportion of arterial thromboses (6.2% vs 3.7%; P = .015). After adjustment for confounders, the occurrence of arterial thrombosis remained independently associated with the risk of carcinoma (odds ratio, 1.97; 95% confidence interval, 1.14-3.41), suggesting that MPN patients experiencing arterial events after MPN diagnosis deserve careful clinical surveillance for early detection of carcinoma. This study was registered at www.clinicaltrials.gov as NCT03745378.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Arterias / Trombosis / Cromosoma Filadelfia / Neoplasias Primarias Secundarias / Trastornos Mieloproliferativos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Humans Idioma: En Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Arterias / Trombosis / Cromosoma Filadelfia / Neoplasias Primarias Secundarias / Trastornos Mieloproliferativos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Humans Idioma: En Año: 2020 Tipo del documento: Article